N/A N=22 Effects of Acute Intermittent Hypoxia on Sensory Function in Healthy Adults
Sensitivity
Primary: Sensory Function — 46.7; 46.4; 46.1; 45.9 Degrees celsius — p=0.592
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,160 Partners-based HIV Treatment for Couples Attending Antenatal Care
Human Immunodeficiency Virus
Primary: Proportion of Time on Medication Among Pregnant Women — 0.67; 0.66 proportion of days with medicaiton
Phase 2 N=97 Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
HIV Infections · Kidney Diseases
Primary: Mean Glomerular Filtration Rate by Iohexol Clearance at Week 52 — 37.0; 40.1 mL/min/1.73 m²
Phase 3 N=71 A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 76.0; 78.6 percentage of participants
N/A N=132 Obstructive Sleep Apnea Endotypes and Impact on Phenotypes of People Living With HIV
Human Immunodeficiency Virus · Obstructive Sleep Apnea
Primary: Reaction Time Measured Using the Psychomotor Vigilance Task — 346; 353; 348 ms
N/A N=24 Benefits of the HiResolution Bionic Ear System in Adults With Asymmetric Hearing Loss
Hearing Loss · Ear Diseases · Hearing Disorders
Primary: Change in Consonant Nucleus-Consonant (CNC) Word Recognition Test (Implanted Ear Only) — 2.13; 61.14 percentage of recognized words
N/A N=43 The Effect of the Erchonia GVL Low Level Laser Therapy on Neck and Shoulder Pain
Musculoskeletal Pain
Primary: Percentage of Subjects With 30% or Greater Change in Pain Rating on the Visual Analog Scale (VAS) — 81.4 percentage of subjects
Phase 1 N=36 Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
Wilson Disease
Primary: Maximum Observed Plasma Concentration (Cmax) Of Celecoxib With And Without The Coadministration Of ALXN1840 — 637.1; 567.4 ng/mL
N/A N=384 Technology-enhanced Transitional Palliative Care for Family Caregivers
Palliative Care
Primary: Change in Preparedness for Caregiving Scale Score — 0.3; 0.0 score on a scale
Phase 2 N=206 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Cancer
Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants
N/A N=215 Post-Market Clinical Investigation of the Clareon® IOL
Cataract · Aphakia
Primary: Percentage of First Implanted Eyes Achieving Best-Corrected Distance Visual Acuity (BCDVA) of 0.3 Logarithm Minimum Angle of Resolution (logMAR) or Better at 1 Year…
N/A N=2,214 Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches
Cigarette Smoking Behavior
Primary: Intention to Quit Smoking — 4.814; 4.844 Score on a scale
N/A N=20 Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator
Type 1 Diabetes Mellitus
Primary: Low Blood Glucose Index (LBGI) — 1.4; 1.9 index score
N/A N=20 Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)
Influenza A H3N2
Primary: Number of PCR-confirmed Influenza Infections — 17; 3 Participants
Phase 1 N=12 A Single Dose Study To Test Two Pediatric Forms Of Ritlecitinib Compared With Adult Ritlecitinib In Healthy Adults
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for Ritlecitinib — 361.1; 370.1; 385.1 nanograms*hours/milliliter…